RxDoctor Payments Data

Dylon Howard, DO

Family Medicine · Ada, OKNPI 1942693023

Payments from drug & device makers

$452in general payments, 2019–2025

Across 26 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$163
  • AbbVie$144
  • Lilly USA, LLC$38
  • Astellas Pharma US Inc$30
  • Abbott$19
  • Novartis$18
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk10$163
AbbVie7$144
Lilly USA, LLC3$38
Astellas Pharma US Inc1$30
Abbott1$19
Novartis1$18
GSK1$15
Amgen1$13
Pfizer1$12

How this compares

$452 in reported general payments places this provider in the 50th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$147,464
Medicare patients
391
Services billed
3,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$105,536
TrulicityDulaglutide85$99,731
EliquisApixaban109$95,417
JardianceEmpagliflozin58$69,375
Tresiba Flextouch U-200Insulin Degludec21$40,361
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$30,196
FarxigaDapagliflozin Propanediol23$22,013
XareltoRivaroxaban28$20,926
LinzessLinaclotide27$19,308
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$16,447
MounjaroTirzepatide15$15,508
Fiasp FlextouchInsulin Aspart (Niacinamide)18$14,719
QuliptaAtogepant13$13,719
TradjentaLinagliptin19$13,660
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$12,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$38$115,239100 claims
Novo NordiskOzempic$163$105,53681 claims
PfizerEliquis$12$95,417109 claims
GSKTrelegy Ellipta, Breo Ellipta$15$39,94260 claims
AbbVieLinzess, Qulipta$144$33,02740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Ada

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →